Molecular dynamics simulations of hydrophilic pores in phospholipid bilayers and Fe3O4 nanoparticles loaded with the 5-fluorouracil anticancer drug
Source abstract
Abstract
Abstract The interaction of a PEGylated and non-PEGylated Fe3O4 nanoparticle drug-delivery system, with 5-fluorouracil (5-FU) as the chemotherapy drug, is investigated via atomistic molecular dynamics (MD). The induced pore formation in a dipalmitoylphosphatidylcholine (DPPC) bilayer phospholipid (BLPL) is studied, and the resulting hourglass-shaped pores with hydrophilic lipid headgroups lining the pores are observed. Furthermore, we optimize the required number of ligands that are required to allow for the formed pores to spontaneously reseal. Additionally, the number of water molecules that transverse through the water bridge is investigated. These results may be useful to design nanocarrier systems that will maintain the cellular osmotic pressure and stability, while the 5-FU is converted to the required metabolites inside the cell to serve its purpose as a chemotherapeutic drug.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Lipid Membrane Structure and Behavior · Nanoparticle-Based Drug Delivery · Nanopore and Nanochannel Transport Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. Pardini B, Kumar R, Naccarati A, Novotny J, Prasad RB, Forsti A, Hemminki K, Vodicka P, Bermejo JL (2011) 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br J Clin Pharmacol 72(1):162–16310.1111/j.1365-2125.2010.03892.x ↗
2. Monge-Fuentes V, Biolchi Mayer A, Lima MR (2021) Dopamine-loaded nanoparticle systems circumvent the blood-brain barrier restoring motor function in mouse model for Parkinson’s disease. Sci Rep 11:1518510.1038/s41598-021-94175-8 ↗
3. Harris RA (2022) The PEGylated and non-PEGylated interaction of the anticancer drug 5-fluorouracil with paramagnetic Fe3O4 nanoparticles as drug carrier. J Mol Liq 360:11951510.1016/j.molliq.2022.119515 ↗
4. Sommer H, Santi DV (1974) Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2′-deoxyuridylate and methylenetetrahydrofolate. Biochem Biophys Res Commun 57:689–69510.1016/0006-291X(74)90601-9 ↗
5. Afzal S, Jensen SA, Vainer B, Vogel U, Matsen JP, Sorensen JB, Andersen PK, Poulsen HE (2009) MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol 20:1660–166610.1093/annonc/mdp046 ↗
6. Canman CE, Lawrence TS, Shewach DS, Tang HY, Maybaum J (1993) Resistance to 5-fluorodeoxyuridineinduced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate. Cancer Res 53:5219–5224
7. Ventura R, Martínez-Ruiz I, Hernández-Alvarez MI (2022) Phospholipid membrane transport and associated diseases. Biomedicines 10(5):120110.3390/biomedicines10051201 ↗
8. Leontaidou H, Mark AE, Marrink SJ (2004) Molecular dynamics simulations of hydrophilic pores in lipid bilayers. Biophys J 86:2156–216410.1016/S0006-3495(04)74275-7 ↗
9. Jansen M, Blume M (1995) A comparative study of diffusive and osmotic water permeation across bilayers composed of phospholipids with different head groups and fatty acyl chains. Biophys J 68:997–100810.1016/S0006-3495(95)80275-4 ↗
10. Deamer DW, Bramhall J (1986) Permeability of lipid bilayers to water and ionic solutes. Chem Phys Lipids 40:167–18810.1016/0009-3084(86)90069-1 ↗
11. Lawaczeck R (1988) Defect structures in membranes: routes for the permeation of small molecules. Ber Bunsenges Phys Chem 92:961–96310.1002/bbpc.198800241 ↗
12. Melikov KC, Frolov VA, Shcherbakov A, Samsonov AV, Chizmadzhev YA, Chernomordik V (2001) Voltage-induced nonconductive pre-pores and metastable single pores in unmodified planar lipid bilayer. Biophys J 80:1829–183610.1016/S0006-3495(01)76153-X ↗
13. Tekle E, Astumian RD, Friauf WA, Chock PB (2001) Asymmetric pore distribution and loss of membrane lipid in electroporated DOPC vesicles. Biophys J 81:960–96810.1016/S0006-3495(01)75754-2 ↗
14. Akinlaja J, Sachs F (1998) The breakdown of cell membranes by electrical and mechanical stress. Biophys J 75:247–25410.1016/S0006-3495(98)77511-3 ↗
15. Zhelev DV, Needham D (1993) Tension-stabilized pores in giant vesicles: determination of pore size and pore line tension. Biochim Biophys Acta 1147:89–10410.1016/0005-2736(93)90319-U ↗
16. Drew Bennett WF, Peter Tieleman D (2011) Water defect and pore formation in atomistic and coarse-grained lipid membranes: pushing the limits of coarse graining. J Chem Theory Comput 7:2971–2988
17. Tieleman DP, MacCallum JL, Ash WL, Kandt C, Xu ZT (2006) Membrane protein simulations with a united-atom lipid and all-atom protein model: lipid-protein interactions, side chain transfer free energies and model proteins. J Phys Cond Matter 18:S1221–S123410.1088/0953-8984/18/28/S07 ↗
18. Henin J, Shinoda W, Klein ML (2008) United-atom acyl chains for CHARMM phospholipids. J Phys Chem B 112:7008–701510.1021/jp800687p ↗
19. Klauda JB, Venable RM, MacKerell AD, Pastor RW (2008) Considerations for lipid force field development. Curr Top Memb 60:1–4810.1016/S1063-5823(08)00001-X ↗
20. Marrink SJ, de Vries AH, Peter Tieleman D (2009) Lipids on the move: simulations of membrane pores, domains, stalks and curves. Biochim Biophys Acta 1788:149–16810.1016/j.bbamem.2008.10.006 ↗
21. Groot RD, Rabone KL (2001) Mesoscopic simulation of cell membrane damage, morphology change and rupture by nonionic surfactants. Biophys J 81:725–73610.1016/S0006-3495(01)75737-2 ↗
22. Marrink SJ, Lindahl E, Edholm O, Mark AE (2001) Simulation of the spontaneous aggregation of phospholipids into bilayers. J Am Chem Soc 123:8638–863910.1021/ja0159618 ↗
23. Wennerström H, Oliveberg M (2022) On the osmotic pressure of cells. QRB Discovery 3(e12):1–10
24. Harris RA (2019) Chemotherapy drug temozolomide adsorbed onto iron-oxide (Fe3O4) nanoparticles as nanocarrier: a simulation study. J Mol Liq 288:11108410.1016/j.molliq.2019.111084 ↗
25. Fröhlich E (2012) The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine 7:5577–559110.2147/IJN.S36111 ↗
26. Tao X, Jin SU, Dehong WU, Ling K, Yuan L, Lin P, Xie Y, Yang X (2016) Effects of particle hydrophobicity, surface charge, media pH value and complexation with human serum albumin on drug release behavior of mitoxantrone-loaded pullulan nanoparticles. Nanomaterials (Basel) 6(1):210.3390/nano6010002 ↗
27. Manish G, Vimukta S (2011) Targeted drug delivery system: a review. Res J Chem Sci 1(2):135–138
28. Harris RA, Shumbula PM, Van der Walt H (2015) Analysis of the interaction of surfactants oleic acid and oleylamine with iron oxide nanoparticles through molecular mechanics modelling. Langmuir 31:3934–394310.1021/acs.langmuir.5b00671 ↗
29. Wang C, Xu X, Qiu G, Ye W, Li Y, Harris RA, Jiang C (2021) Group-targeting SERS screening of total benzodiazepines based on large-size (111) faceted silver nanosheets decorated with zinc oxide nanoparticles. Anal Chem 93(7):3403–341010.1021/acs.analchem.0c04399 ↗
30. Toden S, Tran H-M, Tovar-Camargo OA, Okugawa Y, Goel A (2016) Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget 7:1615810.18632/oncotarget.7567 ↗
31. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM (1994) Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 12(10):2035–4210.1200/JCO.1994.12.10.2035 ↗
32. Sethy C (2021) Chanakya Nath Kundu, 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother 137:11128510.1016/j.biopha.2021.111285 ↗